Paclitaxel nanoformulation - DFB Soria/NanOlogy

Drug Profile

Paclitaxel nanoformulation - DFB Soria/NanOlogy

Alternative Names: NanoPac; Nanotax; SOR 007

Latest Information Update: 14 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DFB Soria; Nanology
  • Developer bioskin; DFB Soria; NanOlogy; US Biotest Inc
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Actinic keratosis; Ovarian cancer; Pancreatic cancer; Pancreatic disorders; Prostate cancer; Skin cancer
  • Phase I Plaque psoriasis
  • Preclinical Cervical intraepithelial neoplasia; Non-small cell lung cancer

Most Recent Events

  • 01 Jun 2018 Pharmacodynamics data from a preclinical trial in Non-small cell lung cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 18 Dec 2017 Phase-II clinical trials in Pancreatic cancer (Late-stage disease, Second-line therapy or greater) in USA (Intratumoural)
  • 14 Nov 2017 NanOlogy has patent protection for its submicron particle technology platform in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top